AR112137A1 - Preparación sólida para administración oral que comprende cariprazina - Google Patents
Preparación sólida para administración oral que comprende cariprazinaInfo
- Publication number
- AR112137A1 AR112137A1 ARP180101591A ARP180101591A AR112137A1 AR 112137 A1 AR112137 A1 AR 112137A1 AR P180101591 A ARP180101591 A AR P180101591A AR P180101591 A ARP180101591 A AR P180101591A AR 112137 A1 AR112137 A1 AR 112137A1
- Authority
- AR
- Argentina
- Prior art keywords
- cariprazine
- oral administration
- solid preparation
- administration including
- modified release
- Prior art date
Links
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 title abstract 3
- 229960005123 cariprazine Drugs 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title 1
- 102000015554 Dopamine receptor Human genes 0.000 abstract 1
- 108050004812 Dopamine receptor Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP1700253 HUP1700253A1 (hu) | 2017-06-13 | 2017-06-13 | Szilárd orális gyógyszerkészítmények |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112137A1 true AR112137A1 (es) | 2019-09-25 |
Family
ID=89992469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101591A AR112137A1 (es) | 2017-06-13 | 2018-06-12 | Preparación sólida para administración oral que comprende cariprazina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200222391A1 (enExample) |
| EP (1) | EP3638210A1 (enExample) |
| JP (1) | JP2020523335A (enExample) |
| KR (1) | KR20200016378A (enExample) |
| CN (1) | CN110769815A (enExample) |
| AR (1) | AR112137A1 (enExample) |
| AU (1) | AU2018284138A1 (enExample) |
| BR (1) | BR112019025214A2 (enExample) |
| CA (1) | CA3064694A1 (enExample) |
| CL (1) | CL2019003619A1 (enExample) |
| CO (1) | CO2020000168A2 (enExample) |
| EA (1) | EA202090029A1 (enExample) |
| HU (1) | HUP1700253A1 (enExample) |
| IL (1) | IL271108A (enExample) |
| MX (1) | MX2019015206A (enExample) |
| PE (1) | PE20200334A1 (enExample) |
| PH (1) | PH12019502566A1 (enExample) |
| TW (1) | TW201906608A (enExample) |
| WO (1) | WO2018229641A1 (enExample) |
| ZA (1) | ZA201908454B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2317852T1 (sl) | 2008-07-16 | 2015-04-30 | Richter Gedeon Nyrt. | Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| US11344503B2 (en) * | 2019-12-13 | 2022-05-31 | Halo Science LLC | Cariprazine release formulations |
| CN114681406B (zh) * | 2020-12-25 | 2023-10-13 | 上海京新生物医药有限公司 | 一种卡利拉嗪长效缓释微球及其制备方法 |
| CN114748428B (zh) * | 2020-12-25 | 2023-05-23 | 上海京新生物医药有限公司 | 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法 |
| WO2023160583A1 (zh) * | 2022-02-22 | 2023-08-31 | 上海云晟研新生物科技有限公司 | 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途 |
| CA3244202A1 (en) | 2022-03-17 | 2023-09-21 | Mapi Pharma Ltd | DEPOSIT SYSTEMS INCLUDING CARIPRAZINE OR SALTS THEREOF |
| HU231682B1 (hu) * | 2022-08-05 | 2025-10-28 | Richter Gedeon Nyrt | Kariprazin tartalmú szájban diszpergálódó tabletta |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6248618A (ja) * | 1985-08-27 | 1987-03-03 | Zeria Shinyaku Kogyo Kk | 徐放性製剤およびその製造法 |
| US5910319A (en) | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
| HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| JP5460594B2 (ja) * | 2007-08-03 | 2014-04-02 | リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグ | ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法 |
| EP2251011B1 (en) * | 2008-02-21 | 2012-04-04 | Richter Gedeon Nyrt. | Solid preparation for oral administration |
| SI2317852T1 (sl) | 2008-07-16 | 2015-04-30 | Richter Gedeon Nyrt. | Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja |
| EA201691582A1 (ru) * | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
| CN106692149A (zh) * | 2015-11-13 | 2017-05-24 | 天津市汉康医药生物技术有限公司 | 一种卡利拉嗪药物口服制剂及其制备方法 |
-
2017
- 2017-06-13 HU HUP1700253 patent/HUP1700253A1/hu unknown
-
2018
- 2018-05-30 TW TW107118464A patent/TW201906608A/zh unknown
- 2018-06-12 US US16/622,020 patent/US20200222391A1/en not_active Abandoned
- 2018-06-12 AU AU2018284138A patent/AU2018284138A1/en not_active Abandoned
- 2018-06-12 JP JP2019568138A patent/JP2020523335A/ja active Pending
- 2018-06-12 EP EP18734306.6A patent/EP3638210A1/en not_active Withdrawn
- 2018-06-12 BR BR112019025214-2A patent/BR112019025214A2/pt not_active Application Discontinuation
- 2018-06-12 AR ARP180101591A patent/AR112137A1/es unknown
- 2018-06-12 KR KR1020207001040A patent/KR20200016378A/ko not_active Ceased
- 2018-06-12 EA EA202090029A patent/EA202090029A1/ru unknown
- 2018-06-12 PE PE2019002491A patent/PE20200334A1/es unknown
- 2018-06-12 CA CA3064694A patent/CA3064694A1/en not_active Abandoned
- 2018-06-12 MX MX2019015206A patent/MX2019015206A/es unknown
- 2018-06-12 WO PCT/IB2018/054227 patent/WO2018229641A1/en not_active Ceased
- 2018-06-12 CN CN201880040070.6A patent/CN110769815A/zh active Pending
-
2019
- 2019-11-15 PH PH12019502566A patent/PH12019502566A1/en unknown
- 2019-12-02 IL IL271108A patent/IL271108A/en unknown
- 2019-12-11 CL CL2019003619A patent/CL2019003619A1/es unknown
- 2019-12-18 ZA ZA2019/08454A patent/ZA201908454B/en unknown
-
2020
- 2020-01-09 CO CONC2020/0000168A patent/CO2020000168A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200016378A (ko) | 2020-02-14 |
| BR112019025214A2 (pt) | 2020-06-16 |
| EP3638210A1 (en) | 2020-04-22 |
| HUP1700253A1 (hu) | 2019-01-28 |
| US20200222391A1 (en) | 2020-07-16 |
| JP2020523335A (ja) | 2020-08-06 |
| EA202090029A1 (ru) | 2020-03-26 |
| PE20200334A1 (es) | 2020-02-14 |
| CO2020000168A2 (es) | 2021-06-21 |
| CL2019003619A1 (es) | 2020-05-15 |
| PH12019502566A1 (en) | 2020-07-20 |
| ZA201908454B (en) | 2021-10-27 |
| TW201906608A (zh) | 2019-02-16 |
| WO2018229641A1 (en) | 2018-12-20 |
| MX2019015206A (es) | 2020-02-10 |
| AU2018284138A1 (en) | 2020-01-16 |
| IL271108A (en) | 2020-01-30 |
| CA3064694A1 (en) | 2018-12-20 |
| CN110769815A (zh) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020000168A2 (es) | Preparación sólida de cariprazina para administración oral | |
| CU20090196A7 (es) | Metabolitos de derivados del (tio)-carbamoil-ciclohexano | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| CR20210061A (es) | Composiciones farmacéuticas que comprenden meloxicam | |
| AR109816A2 (es) | Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2 | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| NI201700101A (es) | Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina | |
| CL2020003101A1 (es) | Sales de sepiapterina farmacéuticamente aceptables. | |
| SMT201300108B (it) | Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina | |
| MX2023014946A (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal. | |
| SA521421645B1 (ar) | بيرولينات إندماجية تعمل كمثبطات بروتياز نوعي لأوبيكويتين 30 | |
| HRP20171908T1 (hr) | Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora | |
| MX2020004107A (es) | Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas. | |
| UA101322C2 (en) | Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-n,n-dimethylcarbamoyl-cyclohexylamine for the treatment of schizophrenia | |
| CY1124733T1 (el) | Antimykhtiaσιko φαρμακευτικο σκευασμα | |
| PE20212067A1 (es) | Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada | |
| PH12020551841A1 (en) | Stable pharmaceutical formulation | |
| ECSP21067104A (es) | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas | |
| MX385513B (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| ECSP078038A (es) | Formulaciones farmacéuticas de liberación inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] no micronizado, y sus sales | |
| MX2018013893A (es) | Composicion topica estable. | |
| CO2018007016A1 (es) | Composiciones farmaceuticas de montelukast y levocetirizina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |